Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Vishal Bhambri
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally
US Endocrinology
Endocrinology
Metabolism
Diabetes
Related publications
Early Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes: Study Based on Continuous Glucose Monitoring
Diabetology and Metabolic Syndrome
Internal Medicine
Endocrinology
Metabolism
Diabetes
Sodium-Glucose Co-Transporter 2 Inhibitors: A Review of Their Use in Older People With Type 2 Diabetes Mellitus
Journal of Pharmacy Practice and Research
Pharmacology
Pharmacy
Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?
Anaesthesia
Anesthesiology
Pain Medicine
Sodium-Glucose Co-Transporter Type-2 Inhibitors: Pharmacology and Peri-Operative Considerations
Anaesthesia
Anesthesiology
Pain Medicine
The Potential Role of Sodium Glucose Co-Transporter 2 Inhibitors in the Early Treatment of Type 2 Diabetes Mellitus
International Journal of Clinical Practice
Medicine
Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through? A Reply
Anaesthesia
Anesthesiology
Pain Medicine
Should Sodium Glucose Co-Transporter 2 Inhibitors Be Considered as First Line Oral Therapy for People With Type 2 Diabetes?
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis
Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Drugs in Context
Molecular Medicine
Pharmacology